Blueprint Medicines Corporation (NASDAQ:BPMC) reported Q3 2017 earnings this Morning, coming in at ($0.96) per share, missing Wall Street’s estimates of ($0.88) per Share. Revenue for the quarter came in at $8.07 million beating analyst estimates of $5.35 million
Analyst Coverage For Blueprint Medicines Corporation (NASDAQ:BPMC)
These are 9 Buy Ratings .
The current consensus rating for Blueprint Medicines Corporation (NASDAQ:BPMC) is Buy (Score: 3.00) with a consensus target price of $67.13 , a potential (2.04% downside)Recent Insider Trading for Blueprint Medicines Corporation (NASDAQ:BPMC)
- On 10/5/2017 Kate Haviland, Insider, sold 5,449 with an average share price of $66.44 per share and the total transaction amounting to $362,031.56.
- On 9/18/2017 Daniel Lynch, Director, sold 2,500 with an average share price of $60.00 per share and the total transaction amounting to $150,000.00.
- On 9/18/2017 Kate Haviland, Insider, sold 6,356 with an average share price of $60.03 per share and the total transaction amounting to $381,550.68.
- On 8/9/2017 Anthony L Boral, Insider, sold 5,000 with an average share price of $48.60 per share and the total transaction amounting to $243,000.00.
- On 8/8/2017 Jeffrey W Albers, CEO, sold 30,000 with an average share price of $49.62 per share and the total transaction amounting to $1,488,600.00.
- On 8/7/2017 Jeffrey W Albers, CEO, sold 20,000 with an average share price of $49.08 per share and the total transaction amounting to $981,600.00.
Recent Trading for Blueprint Medicines Corporation (NASDAQ:BPMC) Shares of Blueprint Medicines Corporation closed the previous trading session at with shares trading hands.